Avsola® (infliximab-axxq)
Inflectra® (infliximab-dyyb)
Remicade® (infliximab)
Renflexis® (infliximab-abda)

Effective 01/01/2022

<table>
<thead>
<tr>
<th>Plan</th>
<th>MassHealth</th>
<th>MassHealth (PUF)</th>
<th>Commercial/Exchange</th>
<th>Program Type</th>
<th>Prior Authorization</th>
<th>Quantity Limit</th>
<th>Step Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefit</td>
<td>Pharmacy Benefit</td>
<td>Medical Benefit (NLX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Specialty Limitations: These medications have been designated specialty and must be filled at a contracted specialty pharmacy.

### Contact Information

<table>
<thead>
<tr>
<th>Specialty Medications</th>
<th>All Plans</th>
<th>Phone: 866-814-5506</th>
<th>Fax: 866-249-6155</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Specialty Medications</td>
<td>MassHealth</td>
<td>Phone: 877-433-7643</td>
<td>Fax: 866-255-7569</td>
</tr>
<tr>
<td>Commercial</td>
<td>Phone: 800-294-5979</td>
<td>Fax: 888-836-0730</td>
<td></td>
</tr>
<tr>
<td>Exchange</td>
<td>Phone: 855-582-2022</td>
<td>Fax: 855-245-2134</td>
<td></td>
</tr>
<tr>
<td>Medical Specialty Medications (NLX)</td>
<td>All Plans</td>
<td>Phone: 844-345-2803</td>
<td>Fax: 844-851-0882</td>
</tr>
</tbody>
</table>

Exceptions: N/A

### Overview

**FDA approved indications:**
- Ankylosing Spondylitis: Avsola®, Inflectra®, Remicade®, Renflexis®
- Crohn’s Disease, Moderate-to-severe: Avsola®, Inflectra®, Remicade®, Renflexis®
- Crohn’s Disease (including fistulizing disease), Moderate-to-severe: Avsola®, Inflectra®, Remicade®, Renflexis®
- Plaque Psoriasis, Moderate-to-severe: Avsola®, Inflectra®, Remicade®, Renflexis®
- Psoriatic Arthritis: Avsola®, Inflectra®, Remicade®, Renflexis®
- Rheumatoid Arthritis (RA), Moderate-to-severe: Avsola®, Inflectra®, Remicade®, Renflexis®
- Ulcerative colitis, Moderate-to-Severe,: Avsola®, Inflectra®, Remicade®, Renflexis®

### Coverage Guidelines

Authorizations requests will be reviewed on a case by case basis for members new to AllWays Health Partners who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org

AllWays Health Partners includes AllWays Health Partners, Inc. and AllWays Health Partners Insurance Company
Authorization may be granted for members when all the following criteria are met, and documentation is provided:

**Moderate-to-severe Rheumatoid arthritis**
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Member meets **ONE** of the following:
   a. Paid claim or provider attestation of inadequate response or adverse reaction to **ONE** traditional DMARD or contraindication to traditional DMARDs
   b. Paid claim or provider attestation of inadequate response or adverse reaction to **ONE** biologic DMARD that is FDA-approved for the requested indication
3. Appropriate dosing
4. Provider provides clinical rationale for use of the requested agent instead of Enbrel® and Humira®

**Psoriatic arthritis**
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Appropriate dosing
3. Provider provides clinical rationale for use of the requested agent instead of Enbrel® and Humira®

**Ankylosing spondylitis**
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Paid claims or physician attestation of inadequate response or adverse reaction to **TWO** NSAIDs or contraindication to **ALL** NSAIDs
3. Appropriate dosing
4. Provider provides clinical rationale for use of the requested agent instead of Enbrel® and Humira®

**Moderate-to-severe plaque psoriasis**
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Member meets **ONE** of the following:
   a. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** conventional therapy (see appendix)
      a. topical agent
      b. phototherapy
      c. systemic agent
   b. Contraindication to **ALL** conventional therapies:
      a. topical agents
      b. phototherapy
      c. systemic agents
   c. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** biologic DMARD that is FDA-approved for plaque psoriasis
3. Appropriate dosing
4. Provider provides clinical rationale for use of the requested agent instead of Enbrel® and Humira®

**Moderate-to-severe Crohn’s disease**
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Appropriate dosing†
3. Provider provides clinical rationale for use of the requested agent instead of Enbrel® and Humira®

**Fistulizing Crohn’s disease**
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Appropriate dosing (see appendix and availability and dosage section) †

**Moderate-to-severe Ulcerative colitis**
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Prescriber is a gastroenterologist or consult notes from a gastroenterology office are provided
3. Member meets **ONE** of the following:
   a. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** anti-TNF agent that is FDA-approved for ulcerative colitis
   b. Contraindication to **ALL** anti-TNF agents
4. The member has had inadequate response, adverse reaction, or contraindication to Entyvio®
5. Appropriate dosing
6. Member is not currently receiving concomitant therapy with immunomodulators or biologic agents

**Continuation of Therapy**
Resubmission by prescriber for any of the following FDA-approved diagnoses will infer a positive response to therapy and request can be recertified if dosing is appropriate.

**Limitations**
1. Initial authorizations will be granted for:
   a. For the diagnosis of Ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis: **6 months**
   b. For the diagnosis of Plaque psoriasis and Off label indications (referenced in appendices): **3 months**
2. Reauthorizations for all diagnoses will be granted for **12 months**

**Appendices**

**Appendix A: Traditional DMARDs**

<table>
<thead>
<tr>
<th>Traditional DMARDS*</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>azathioprine</td>
<td>methotrexate*</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>sulfasalazine*</td>
</tr>
<tr>
<td>hydroxychloroquine*</td>
<td>thalidomide</td>
</tr>
<tr>
<td>leflunomide</td>
<td></td>
</tr>
</tbody>
</table>

If a member has a contraindication to **ALL** of the most commonly used traditional DMARDs* (methotrexate, sulfasalazine, and hydroxychloroquine), a trial with a traditional DMARD may be bypassed.

**Appendix B. Conventional Therapies for Plaque Psoriasis**
### Conventional Treatment Lines

<table>
<thead>
<tr>
<th>Topical Agents</th>
<th>Agents Used</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>emollients, keratolytics, corticosteroids, coal tar, anthralin, calcipotriene, tazarotene, calcitriol, calcineurin inhibitors</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Systemic Agents</th>
<th>Agents Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Traditional DMARDs: methotrexate, apremilast, acitretin, calcitriol</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phototherapy</th>
<th>Agents Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA), narrow band UV-B (NUVB)</td>
<td></td>
</tr>
</tbody>
</table>

### Appendix C: Off-Label Indications

#### More frequent/Higher doses
Requests more frequent or higher doses of injectable biologics, may be approved if ALL of the following is provided:

1. Documentation of severe disease
2. **ONE** of the following:
   a. Inadequate response or adverse reaction to **ONE** other injectable biologic which is FDA-approved for the requested indication*
   b. Contraindication to **ALL** other injectable biologics which are FDA-approved for the requested indication
3. Documented partial response to FDA-approved dosing of current biologic therapy
4. Documentation of specialist consult for the requested indication

*A trial with another injectable biologic may be bypassed if:
- The requested regimen is Avsola® (infliximab-axxq), Inflectra® (infliximab-dyyb), Remicade® (infliximab), or Renflexis® (infliximab-abda) for Crohn’s disease or ulcerative colitis and the request documents low drug levels and no/low antibodies. The recommended trough level for infliximab is greater than or equal to 5 mcg/mL in patients with inflammatory bowel disease.

### Hydradenitis Suppurativa

Prescriber provides documentation of **ALL** of the following:

1. Diagnosis of moderate to severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease)
2. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** oral antibiotic or contraindication to **ALL** oral antibiotics (e.g. rifampin, clindamycin, tetracycline, doxycycline, minocycline)
3. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to Humira® (adalimumab)
4. Appropriate dosing: Avsola® (infliximab-axxq), Inflectra® (infliximab-dyyb), Remicade® (infliximab), or Renflexis® (infliximab-abda): 5 mg/kg on week 0, 2 and 6 then every 8 weeks,

### Uveitis

Prescriber provides documentation of **ALL** of the following:

1. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to **ALL** of the following:
   a. Ophthalmic (topical) or oral glucocorticoids
   b. Oral or injectable immunosuppressive therapy (e.g., azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus and cyclophosphamide)
   c. **ONE** of the following:
i. Paid claims or physician attestation of Inadequate response, adverse reaction or contraindication to Humira® (adalimumab)

ii. Clinical rationale for use of Avsola® (infliximab-axxq), Remicade® (infliximab), Inflectra® (infliximab-dyyb), or Renflexis® (infliximab-abda) instead of Humira® (adalimumab)

**Scleritis**

Prescriber provides documentation of ALL of the following:

1. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to ALL of the following:
   a. Ophthalmic (topical) or oral glucocorticoids
   b. Oral or injectable immunosuppressive therapy (e.g., azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus and cyclophosphamide)

**Pulmonary Sarcoidosis**

Prescriber provides documentation of ALL of the following:

1. Member has an appropriate diagnosis of sarcoidosis with pulmonary involvement
2. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to ALL of the following:
   a. Systemic glucocorticoids
   b. ONE traditional DMARD (methotrexate, azathioprine, leflunomide, or mycophenolate)
   c. ONE of the following:
      i. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to Humira® (adalimumab)
      ii. Clinical rationale for use of Avsola® (infliximab-axxq), Remicade® (infliximab), Inflectra® (infliximab-dyyb), or Renflexis® (infliximab-abda) instead of Humira® (adalimumab)

**Takayasu Arteritis (TAK)**

Prescriber provides documentation of ALL of the following:

1. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to ALL of the following:
   a. Systemic glucocorticoids
   b. One traditional DMARD (methotrexate, azathioprine, leflunomide, or mycophenolate)
   c. ONE of the following:
      i. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to Humira® (adalimumab) and Enbrel® (etanercept)
      ii. Clinical rationale for use of Avsola® (infliximab-axxq), Remicade® (infliximab), Inflectra® (infliximab-dyyb), or Renflexis® (infliximab-abda) instead of Humira® (adalimumab) and Enbrel® (etanercept)

**References**

1. Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc; June 2018.
3. Inflectra (infliximab dyyb) [prescribing information]. New York, NY: Pfizer; November 2017


Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2017


**Review History**
11/17/2021 – Created and Reviewed Nov P&T; switched from CVS SGM to Custom criteria; matched with MH UPPL. Effective 01/01/2022

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.